benzyl 6-(tosyloxy)hexanoate | 1334402-00-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl 6-(tosyloxy)hexanoate
• 英文别名: 5-Tosyloxy-pentanecarboxylic acid benzyl ester；benzyl 6-(4-methylphenyl)sulfonyloxyhexanoate
• CAS: 1334402-00-4
• 化学式: C₂₀H₂₄O₅S
• 分子量: 376.474
• InChiKey: BIXNIYINNLZFLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzyl 6-(tosyloxy)hexanoate 在 palladium on carbon 、 氢气 、 potassium carbonate 、 三乙胺 、 potassium iodide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 5-(6-(4-((1r,3r)-3-(5-(5H-pyrido[4,3-b]indol-7-yl)pyridin-2-yloxy)cyclobutoxy)piperidin-1-yl)-6-oxohexyloxy)-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dione
  参考文献：
  名称：

  TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

  摘要：

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。

  公开号：

  US20180125821A1
• 作为产物：
  描述：

  6-oxohexyl 4-methylbenzenesulfonate 在 三乙胺 、 p-(trifluoromethyl)phenyl(difluoro)-λ3-bromane 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 benzyl 6-(tosyloxy)hexanoate
  参考文献：
  名称：

  Oxidation of Primary Aliphatic and Aromatic Aldehydes with Difluoro(aryl)-λ³-bromane

  摘要：

  Oxidation of primary aliphatic aldehydes with p-trifluoromethylphenyl(difluoro)-lambda(3)-bromane in dichloromethane at 0 degrees C afforded acid fluorides selectively In good yields, while that of aromatic aldehydes In chloroform at room temperature produced aryl difluoromethyl ethers. A larger migratory aptitude of aryl groups compared to primary alkyl groups during a 1,2-shift from carbon to an electron-deficient oxygen atom in bromane(III) Criegee-type intermediates will result in these differences in the reaction courses.

  DOI：

  10.1021/ol202248x

文献信息

• Process for the production of peracylated 1-0-glycosides
  申请人：Schering AG

  公开号：US20030069402A1

  公开（公告）日：2003-04-10

  The invention relates to a process for the production of peracylated 1-O-glycosides of general formula I or salts thereof 1 in which sugar is a monosaccharide that is functionalized in 1-OH-position, R represents methyl, ethyl, propyl, isopropyl, tbutyl, phenyl, n means 2, 3 or 4, X means —COO— or —NH—and L means a straight-chain, branched, saturated or unsaturated C 1 -C 30 carbon chain, which optionally is interrupted or substituted by groups. The process according to the invention starts from economical starting materials, provides good yields and allows the production of peracylated saccharides with 1-O-functionalized side chains on an enlarged scale.

  该发明涉及一种生产通式I的过酰化1-O-糖苷或其盐的工艺，其中糖是在1-OH位置上被官能化的单糖，R代表甲基、乙基、丙基、异丙基、叔丁基、苯基，n取2、3或4，X代表—COO—或—NH—，L代表一条直链、分支、饱和或不饱和的C1-C30碳链，该碳链可以被基团中断或取代。根据该发明的工艺从经济实惠的起始材料开始，提供良好的产量，并允许在扩大规模上生产具有1-O官能化侧链的过酰化糖苷。
• WO2021011913A5
  申请人：——

  公开号：WO2021011913A5

  公开（公告）日：2023-07-25
• TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：EP3999182A1

  公开（公告）日：2022-05-25
• US6831164B2
  申请人：——

  公开号：US6831164B2

  公开（公告）日：2004-12-14
• [EN] TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE<br/>[FR] PROTACS CIBLANT LA PROTÉINE TAU ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：ARVINAS INC

  公开号：WO2018102067A2

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.